| SEC For | m 4 | | | | | | | | | | | | | | | | | |
|---|---|--|--|---------|--|----------|--|-----|--|--------------------|--|--|--|---|--|---|---|--|
| FORM 4 UNITED S | | | | | TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | OMB APPROVAL | | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | NT OF CHANGES IN BENEFICIAL OWNERSHIP | | | | | | | | | Estim | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | |
| 1. Name and Address of Reporting Person [*] Koehler Maria | | | | | or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol <u>Silverback Therapeutics, Inc.</u> [SBTX] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
| (Last) (First) (Middle) C/O SILVERBACK THERAPEUTICS, INC. | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/10/2022 | | | | | | | | Officer (give title Other (specify below) below) | | | | | |
| 500 FAIRVIEW AVENUE N. SUITE 600 | | | | | 4.1 | Line) | | | | | | | | · | | | | |
| · , | Street) SEATTLE WA 98109 | | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) | (S | tate) | | | | | | | | | | | | | | | | |
| | | | ole I - Nor | - | | | | | quired, D | - | | | - | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | | ear) I | 2A. Deemed Execution Date if any (Month/Day/Yea | | Code (Ins | on Dispose | ties Acquired (A) or I Of (D) (Instr. 3, 4 and | | Beneficia Owned F | es ally following | Form (D) o | n: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | | Code V | Amount | (A) o (D) | Price | Price Reported Transactior (Instr. 3 and | | | | (Instr. 4) | |
| | | - | | | | | | | uired, Dis s, options, | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Day | Date, T | ransaction ode (Instr. | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exerv Expiration D (Month/Day/ | ate | 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securitie: Beneficia Owned Following Reported Transacti (Instr. 4) | e s illy g | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | C | ode | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (right to buy) | \$ 4.18 | 06/10/2022 | | | A | | 18,000 | | (1) | 06/09/2032 | Common Stock | 18,000 | \$0.00 | 18,00 | 0 | D | | |

Explanation of Responses:

1. The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Remarks:

/s/ Jeffrey C. Pepe, Attorney-in-06/13/2022

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.